What is Pharmacovigilance?
It encompasses the scientific studies with regard to the detection, evaluation, identification and prevention of adverse (side) effects and other issues relating to human medicinal products. Pharmacovigilance can be defined as "the collection of clinical data relating to the safety of drugs within daily clinical practice, follow-up of the problems encountered during the administration of drugs, identification, determination, research, recording, announcement of underlying causes and taking the necessary measures."
Pharmacovigilance Studies in our Country:
Turkish Center for Monitoring and Evaluating Adverse Drug Effects (TADMER) was founded in 1985, and accepted as the 27th member to the WHO Collaborating Centre for International Drug Monitoring in 1987. The name of the center, Turkish Center for Monitoring and Evaluating Adverse Drug Effects (TADMER) has been changed to Turkish Pharmacovigilance Center (TÜFAM). "Regulation on Monitoring and Evaluation of the Safety of Human Medicinal Products" was first issued on 22.03.2005, and later replaced by the "Regulation on the Safety of Drugs" issued in the Official Gazette dated 15/4/2014 with number 28973 prepared in parallel to the Directive No 2010/84/EC of the current regulation by the European Union related to drugs.